相关实验视频

Updated: Jan 12, 2026

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Network Pharmacology Prediction and Metabolomics Validation of the Mechanism of Fructus Phyllanthi against Hyperlipidemia

Published on: April 7, 2023

不是所有的纤维都平等:从生物学和临床试验中学习

Alberto Zambon¹, Bart Staels², Michel Farnier³

¹Department of Medicine, University of Padua, Padua, Italy.

Atherosclerosis

|October 31, 2025

概括

费诺纤维酸与他类药物相结合,通过降低诸如阿波利波蛋白B (apoB) 等异性质脂质,有效降低其余心血管疾病风险. 这种组合疗法为高风险患者的失脂症管理提供了耐受性良好和安全的选择.

科学领域:

心脏病学心脏病学
内分泌学在内分泌学.
药理学药理学是指药理学的学科.

背景情况:

动脉性脂质失调症是2型糖尿病,肥胖和代谢障碍患者的重要心血管疾病 (CVD) 风险因素.
标准的他类药物治疗往往无法解决残留心血管疾病风险,即使控制低密度脂蛋白胆固醇 (LDL-C).
脂蛋白B (apoB) 和非高密度脂蛋白胆固醇 (非高密度脂蛋白胆固醇-C) 是在动脉质失脂症中残留风险和治疗目标的优质标记物.

研究的目的:

评估纤维酸盐,特别是纤维酸盐,与他类药物结合用于治疗动脉血症的疗效.
评估纤维酸对阿波利波蛋白B (apoB) 水平的影响及其在减少残留心血管疾病风险方面的作用.
审查现实世界的证据和临床试验数据,以检查芬芳纤维酸-他类药物联合治疗的安全性和有效性.

主要方法:

对研究纤维酸盐-他酸盐组合疗法的研究分析,以治疗动脉性脂质失调症.
对不同纤维素 (纤维素,纤维素,纤维素,纤维素) 对apoB和非HDL-C水平的影响进行比较.
对现实世界疗效数据和心血管结局试验的审查,包括长期安全性研究.

主要成果:

与gemfibrozil和pemafibrate不同的是,当与他类药物一起使用时,纤维酸有效地降低了apoB水平.
费诺纤维酸和他类药物的组合导致异位性脂质 (apoB/非HDL-C) 和相关心血管疾病风险的显著降低.
现实世界的研究和结果试验支持纤维酸-他类药物组合作为耐受性良好和有效的治疗选择,可获得长期安全数据长达20年.

结论:

与他类药物结合的纤维酸是一种有价值的策略,用于管理动脉动脉性脂质失调症并降低残留心血管疾病风险.
费诺纤维酸的降低apoB水平的能力使其成为这种组合治疗中比其他纤维酸更受欢迎的选择.
费诺纤维酸与他类药物的长期使用得到了现实世界的证据的支持,证明了高风险患者群体的有效性和安全性.

更多相关视频

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Differential Effects of Lipid-lowering Drugs in Modulating Morphology of Cholesterol Particles

Published on: November 10, 2017

Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening

Advancements in the Metabolic Profiling of Three-Dimensional Brain Tumor Spheroids for Drug Screening

Published on: September 5, 2025

相关概念视频

Ultrasound II: Endoscopic Ultrasound and FibroScan

Ultrasound II: Endoscopic Ultrasound and FibroScan

Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...

Factors Affecting Drug Biotransformation: Biological

Factors Affecting Drug Biotransformation: Biological

Biological factors significantly impact drug metabolism, influencing drug clearance, efficacy, and potential toxicity.
Species differences: Variations in enzyme systems across species can cause disparities in drug metabolism. For instance, humans may metabolize certain drugs faster than rodents, altering therapeutic effects.
Strain differences: Genetic variations within a species can result in differing enzyme activity, impacting drug response and toxicity. For example, some mouse strains may...

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...